(E)-3PO is a small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM) which target: PFKFB3 isozyme. 3PO inhibits recombinant PFKFB3 activity, suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH in vitro.

(E)-3PO is a small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM) which target: PFKFB3 isozyme. 3PO inhibits recombinant PFKFB3 activity, suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH in vitro.

This is a Chinese Pharmacopoeia compound.

Coniferin is an important precursor of the cell-wall constituent lignin.

Coniferin is an important precursor of the cell-wall constituent lignin.

(E)-Dec-2-enoic acid is an interesting fatty acid isolated from royal jelly secretions of honey bees.

(E)-Dec-2-enoic acid is an interesting fatty acid isolated from royal jelly secretions of honey bees.

This is a Chinese Pharmacopoeia compound.

This is a Chinese Pharmacopoeia compound.

Ethyl caffeate, a natural product isolated and purified from the roots of Ferula assafoetida L., has anti-inflammatory activity, and strongly inhibits neoplastic transformation of JB6 Cl41 cells without toxicity.

4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. 4-Hydroxytamoxifen is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent […]

4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. 4-Hydroxytamoxifen is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent […]

[Pyr1]-Apelin-13 is a potent peptide apelin agonist with EC50 of 0.37 nM.

[Pyr1]-Apelin-13 is a potent peptide apelin agonist with EC50 of 0.37 nM.

[Pyr1]-Apelin-13 is a potent peptide apelin agonist with EC50 of 0.37 nM.

(R,S)-Dihydroactinidiolide is the racemic form of Dihydroactinidiolide.

This is a Chinese Pharmacopoeia compound.

(R)-9-(2-Hydroxypropyl)adenine is an intermediate for tenofovir.

This is a Chinese Pharmacopoeia compound.

This is a Chinese Pharmacopoeia compound.

(R)-5-Oxopyrrolidine-2-carboxylic acid is an endogenous metabolite.

(R)-Baclofen HCl is a derivative of gamma-aminobutyric acid (GABA) primarily used to treat spasticity and is in the early research stages for use for the treatment of alcoholism.

(R)-Baclofen HCl is a derivative of gamma-aminobutyric acid (GABA) primarily used to treat spasticity and is in the early research stages for use for the treatment of alcoholism.

(R)-Baclofen HCl is a derivative of gamma-aminobutyric acid (GABA) primarily used to treat spasticity and is in the early research stages for use for the treatment of alcoholism.

(R)-Baclofen HCl is a derivative of gamma-aminobutyric acid (GABA) primarily used to treat spasticity and is in the early research stages for use for the treatment of alcoholism.

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 – 0.07 and 0.09 – 0.8 μM for cdk2 and cdk1,respectively.

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 – 0.07 and 0.09 – 0.8 μM for cdk2 and cdk1,respectively.

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 – 0.07 and 0.09 – 0.8 μM for cdk2 and cdk1,respectively.

(R)-Flurbiprofen is the R-enantiomer of the racemate NSAID flurbiprofen, inhibiting the binding of [3H]9-cis-RA to RXRαLBD with IC50 of 75 μM.

(R)-Flurbiprofen is the R-enantiomer of the racemate NSAID flurbiprofen, inhibiting the binding of [3H]9-cis-RA to RXRαLBD with IC50 of 75 μM.